-
Potential Parkinson’s Treatment, DNS201, Safe and Well-Tolerated in Phase 1 Study, Denali Says
Denali Therapeutics’ reports that DNL201, an LRRK2 inhibitor, was seen to be safe in healthy people and may advance into a trial in Parkinson’s patients.
Read more abuot this study here.
What do you think about this news?
Sorry, there were no replies found.
Log in to reply.